Therefore, the in-depth study of PD-L1, CD86, and CD206 could not only find biomarkers for prognosis assessment of patients with liver cancer, but also provide new therapeutic targets for the immunotherapy of the patients. This evidence concerns the gene MRC1 and liver cancer.